Extended Treatment Duration for Hepatitis C Virus Type 1: Comparing 48 Versus 72 Weeks of Peginterferon-Alfa-2a Plus Ribavirin-Reference-Cited by-同舟云学术

Extended Treatment Duration for Hepatitis C Virus Type 1: Comparing 48 Versus 72 Weeks of Peginterferon-Alfa-2a Plus Ribavirin

Published:2006-04 Issue:4 Volume:130 Page:1086-1097
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

Berg Thomas,von Wagner Michael,Nasser Samer,Sarrazin Christoph,Heintges Tobias,Gerlach Tilman,Buggisch Peter,Goeser Tobias,Rasenack Jens,Pape Gerd R.,Schmidt Wolfgang E.,Kallinowski Birgit,Klinker Hartwig,Spengler Ulrich,Martus Peter,Alshuth Ulrich,Zeuzem Stefan

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference23 articles.

1. Hepatitis C;Di Bisceglie;Lancet,1998

2. Hepatitis C;Marcellin;J Hepatol,1999

3. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C;Manns;Lancet,2001

4. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection;Fried;N Engl J Med,2002

5. Peginterferon alfa-2a in patients with chronic hepatitis C;Zeuzem;N Engl J Med,2000

Cited by 444 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C;World Journal of Gastroenterology;2023-02-14

2. Breakthroughs in hepatitis C research: from discovery to cure;Nature Reviews Gastroenterology & Hepatology;2022-05-20

3. The curing regimens of HCV: A SWOT analysis;Antiviral Therapy;2022-04

4. Antivirals against HCV infection: the story thus far;The Journal of Infection in Developing Countries;2022-02-28

5. RASSF1A and p16 promoter methylation and treatment response in chronic hepatitis C genotype 1b patients treated with pegylated interferon/ribavirin;Archives of Biological Sciences;2022